# SystImmune / Sichuan Biokin

Source: https://onco.cc/companies/systimmune/  
OnCo record `systimmune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SystImmune developed iza-bren, the first bispecific ADC to win a phase 3 trial.

## Summary

SystImmune, headquartered in Redmond, Washington, with its parent Sichuan Biokin in Chengdu, developed izalontamab brengitecan, or iza-bren, the first bispecific antibody-drug conjugate to win a phase 3 trial. Iza-bren targets EGFR and HER3 at once and is partnered with Bristol Myers Squibb in a deal worth up to 8.4 billion dollars, and a pipeline of further bispecific ADCs, including trastuzumab brengitecan, follows it. OnCo links it to triple-negative and HER2-positive breast cancer and oesophageal cancer, to the bispecific ADC technology, to Sichuan Cancer Hospital, to Li Zhang, and to the idea of two-target antibody drugs that close the antigen escape route. Acquired resistance to every therapy is the bottleneck the bispecific design is meant to address. Izalontamab brengitecan has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Sichuan Baili Pharmaceutical Co., Ltd.; Sichuan Baili Pharmaceutical; Baili-Bio
- HQ: Redmond, WA / Chengdu
- Type: biotech
- Website: https://www.systimmune.com

## Sources

- Official website: https://www.systimmune.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [SI-B001](https://onco.cc/drugs/si-b001/), [Trastuzumab brengitecan](https://onco.cc/drugs/trastuzumab-brengitecan/)
- trials: [A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma](https://onco.cc/trials/nct05943795/), [A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC](https://onco.cc/trials/nct05054439/), [A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC](https://onco.cc/trials/nct05044897/), [A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa](https://onco.cc/trials/nct07502300/), [A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s](https://onco.cc/trials/nct07640789/), [A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line](https://onco.cc/trials/nct07739199/), [A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)](https://onco.cc/trials/nct06857175/), [A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)](https://onco.cc/trials/nct07648914/), [A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)](https://onco.cc/trials/nct06343948/), [A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct06382129/), [A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)](https://onco.cc/trials/nct06118333/), [A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)](https://onco.cc/trials/nct06382116/), [A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK](https://onco.cc/trials/nct06994195/), [A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)](https://onco.cc/trials/nct06500026/), [A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)](https://onco.cc/trials/nct07582315/), [A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment](https://onco.cc/trials/nct07518147/), [A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct07678957/), [A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F](https://onco.cc/trials/nct07730489/), [A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer](https://onco.cc/trials/nct06316531/), [A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f](https://onco.cc/trials/nct07739186/), [A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma](https://onco.cc/trials/nct06405425/), [A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer](https://onco.cc/trials/nct07054567/), [A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ](https://onco.cc/trials/nct05880706/), [A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07827261/), [A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU](https://onco.cc/trials/nct07642024/), [A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct06498986/), [A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas](https://onco.cc/trials/nct06838273/), [A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)](https://onco.cc/trials/nct07554456/), [A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma](https://onco.cc/trials/nct06787664/), [A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors](https://onco.cc/trials/nct05785039/), [A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies](https://onco.cc/trials/nct05803018/), [A Study of BL-B01D1 in Patients With Recurrent Glioblastoma](https://onco.cc/trials/nct06598787/), [A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera](https://onco.cc/trials/nct07729956/), [A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer](https://onco.cc/trials/nct05924841/), [A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies](https://onco.cc/trials/nct05990803/), [A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor](https://onco.cc/trials/nct06006169/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct06437509/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ](https://onco.cc/trials/nct06475300/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct06437522/), [A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer](https://onco.cc/trials/nct06471205/), [A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer](https://onco.cc/trials/nct06978114/), [A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer](https://onco.cc/trials/nct06962787/), [A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors](https://onco.cc/trials/nct05949619/), [A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M](https://onco.cc/trials/nct07518173/), [A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS](https://onco.cc/trials/nct07264816/), [A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors](https://onco.cc/trials/nct06031584/), [A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies](https://onco.cc/trials/nct06131450/), [A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer](https://onco.cc/trials/nct06114511/), [A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06957886/), [A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure](https://onco.cc/trials/nct07606599/), [A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy](https://onco.cc/trials/nct06830889/), [A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC](https://onco.cc/trials/nct07178795/), [A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea](https://onco.cc/trials/nct06891833/), [A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ](https://onco.cc/trials/nct06445400/), [A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct07255872/), [A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07654400/), [A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies](https://onco.cc/trials/nct05944978/), [A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies](https://onco.cc/trials/nct06066203/), [A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL](https://onco.cc/trials/nct05627856/), [A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct05623982/), [A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)](https://onco.cc/trials/nct05192486/), [A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq](https://onco.cc/trials/nct06668961/), [A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct05668858/), [A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05949606/), [A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other](https://onco.cc/trials/nct05956587/), [A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors](https://onco.cc/trials/nct05965856/), [A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer](https://onco.cc/trials/nct06042894/), [A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ](https://onco.cc/trials/nct06008054/), [BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)](https://onco.cc/trials/nct07625644/), [SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.](https://onco.cc/trials/nct05020457/), [SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05020769/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- technologies: [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- people: [Li Zhang](https://onco.cc/people/zhang-li-sysucc/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/)
- ideas: [Two-target antibody drugs to close the antigen escape route](https://onco.cc/ideas/idea-bio1-dual-antigen-adc-escape/)
- institutions: [Sichuan Cancer Hospital](https://onco.cc/institutions/sichuan-cancer-hospital/)

---
JSON: https://onco.cc/api/v1/entities/systimmune.json